USA-based specialty drugmaker Synovics Pharmaceuticals says that its whollyowned subsidiary, ANDAPharm, has filed an Abbreviated New Drug Application with the US Food and Drug Administration, seeking approval for a 10mg dose of its antihistamine Atarax (hydroxyzine HCl).
John Copanos, ANDAPharm chief executive, said that the filing, which is the firm's first for a prescription drug, marked an important step towards improving its product portfolio. He went on to say: "we are in the process of completing and filing follow-on ANDA for 25mg and 50mg doses of this product."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze